The global facial injectable market size is expected to reach around US$ 28.13 billion by 2030 from US$ 12.25 billion in 2021 and is expected to grow at an impressive double-digit rate of 9.7% from 2022 to 2030.
The study includes drivers and restraints of this market. The study provides an analysis of the global facial injectable market for the period 2017-2030, wherein 2022 to 2030 is the forecast period and 2021 is considered as the base year.
Our Free Sample Reports Includes:
- In-depth Industry Analysis, Introduction, Overview, and COVID-19 Pandemic Outbreak.
- Impact Analysis 180+ Pages Research Report (Including latest research).
- Provide chapter-wise guidance on request 2022 Updated Regional Analysis with Graphical Representation of Trends, Size, & Share, Includes Updated List of figures and tables.
- Updated Report Includes Major Market Players with their Sales Volume, Business Strategy and Revenue Analysis by using Precedence Research methodology.
Download Free Sample Copy Here (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/sample/1594
Research Methodology
A unique research methodology has been utilized to conduct comprehensive research on the growth of the global facial injectable market and arrive at conclusions on the future growth prospects of the market. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the draw conclusions. Secondary sources referred to by analysts during the production of the global market report include statistics from company annual reports, SEC filings, company websites, World Bank database, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of our study on the market as a primary source.
These primary and secondary sources provided exclusive information during interviews, which serves as a validation from mattress topper industry leaders. Access to an extensive internal repository and external proprietary databases allows this report to address specific details and questions about the global facial injectable market with accuracy. The study also uses the top-down approach to assess the numbers for each segment and the bottom-up approach to counter-validate them. This has helped to estimates the future prospects of the global market more reliable and accurate.
Report Highlights
- Based on the product, the botulinum toxin Type A segment dominated the global facial injectable market in 2020 with highest market share. The botulinum toxin Type A in its cosmetic version, known to patients as Botox, is a popular injection that temporarily reduces or removes facial small lines and wrinkles. The forehead creases and frown lines are the most typically treated locations.
- North America is the largest segment for facial injectable market in terms of region. North America controlled the facial injectable market and has a high level of knowledge regarding the state of healthcare and its costs.
- Asia-Pacific region is the fastest growing region in the facial injectable market. The higher awareness about aesthetic surgical procedures, the presence of key market players, and an increasing geriatric population, technological advancements, and demand for minimally invasive aesthetic procedures are some of the factors driving the growth of the facial injectable market in the Asia-Pacific region.
Market Dynamics
Drivers
Surge in demand for aesthetic procedures
The increased awareness has resulted in an increase in demand for aesthetic procedures. Furthermore, as developing countries around the world improve economically, disposable income has risen dramatically. As a result, an increasing number of people are opting for various filler injections to improve their aesthetic appearance. There has also been a considerable shift in attitudes about these cosmetic treatments, reducing the stigma associated with them. As a result, the surge in demand for aesthetic procedures will drive the growth of the global facial injectable market during the forecast period.
Restraints
High cost of facial injectables
The average cost of hyaluronic acid fillers is $682 per syringe, according to American Society of Plastic Surgeons (ASPS) price data from 2018. To attain the intended results, most people will need more than one syringe. Botox, on the other hand, is sold in units and costs between $10 and $15 each unit. For example, to treat the forehead and eye area, an average dosage of 30-40 units might be employed, resulting in a total cost of $300 to $600. Thus, the high cost of facial injectables is hindering the market growth.
Opportunities
Surge in adoption of facial injectable
An increasing proportion of the male population is predicted to adopt facial injectable in the forecast period, which is one of the most unique and widespread trends in the worldwide market. During the forecast period, this particular trend is expected to contribute positively to the facial injectable market growth. Additionally, because males do not want a more apparent improvement of their facial characteristics, less invasive procedures such as botulinum toxin are a popular alternative. More males are predicted to use facial injectables rather than invasive cosmetic procedures as a result of this. The facial injectable growth is projected to be aided by such developments.
Challenges
Side effects of the treatments
The market for facial injectables is projected to be hampered by the negative effects associated with dermal injectables over the forecast period. The injection technique used by the healthcare provider, for example, can influence whether or not the patient has bruise and stiffness. The rapid filler injection and the use of large number of fillers have all been proven to enhance the risk of bruising. Furthermore, if the filler is injected too superficially, it can create a bluish discoloration of the skin covering the filler in some cases. As a result, the side effects of the treatments are a major challenge for the growth of the global facial injectable market during the forecast period.
Why should you invest in this report?
If you are aiming to enter the global facial injectable market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for facial injectable are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2022-2030, so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Some of the prominent players in the global facial injectable market include:
- Johnson & Johnson
- Syneron Candela
- Lumenis
- Hologic
- Solta Medical
- Alma Laser
- Galderma
- Dickinson and Company
- Antares Pharma
- Novartis AG
Market Segmentation:
By Product
- Collagen
- Hyaluronic Acid (HA)
- Botulinum Toxin Type A
- Calcium Hydroxylaptite (CaHA)
- Polymer Fillers
- Others
By Application
- Aesthetics
- Therapeutics
End User
- Hospitals
- Specialty Clinics
- Spa & Beauty Clinics
By Generation
- Gen X
- Boomer
- Millennials
Regional Analysis:
The geographical analysis of the global facial injectable market has been done for North America, Europe, Asia-Pacific, and the Rest of the World.
The North American Market is again segmented into the US, Canada, and Mexico. Coming to the European Market, it can be segmented further into the UK, Germany, France, Italy, Spain, and the rest. Coming to the Asia-Pacific, the global facial injectable Market is segmented into China, India, Japan, and Rest of Asia Pacific. Among others, the market is segmented into the Middle East and Africa, (GCC, North Africa, South Africa and Rest of the Middle East & Africa).
Key Questions Answered by the Report:
- What will be the size of the global facial injectable market in 2030?
- What is the expected CAGR for the facial injectable market between 2021 and 2030?
- Which are the top players active in this global market?
- What are the key drivers of this global market?
- How will the market situation change in the coming years?
- Which region held the highest market share in this global market?
- What are the common business tactics adopted by players?
- What is the growth outlook of the global facial injectable market?
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Facial Injectable Market
5.1. COVID-19 Landscape: Facial Injectable Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Facial Injectable Market, By Product
8.1. Facial Injectable Market, by Product Type, 2022-2030
8.1.1. Collagen
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Hyaluronic Acid (HA)
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Botulinum Toxin Type A
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Calcium Hydroxylaptite (CaHA)
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Polymer Fillers
8.1.5.1. Market Revenue and Forecast (2017-2030)
8.1.6. Others
8.1.6.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Facial Injectable Market, By Application
9.1. Facial Injectable Market, by Application, 2022-2030
9.1.1. Aesthetics
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Therapeutics
9.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Facial Injectable Market, By End User
10.1. Facial Injectable Market, by End User Type, 2022-2030
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Specialty Clinics
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Spa & Beauty Clinics
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Facial Injectable Market, By Generation
11.1. Facial Injectable Market, by Generation Type, 2022-2030
11.1.1. Gen X
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Boomer
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Millennials
11.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Facial Injectable Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Product (2017-2030)
12.1.2. Market Revenue and Forecast, by Application (2017-2030)
12.1.3. Market Revenue and Forecast, by End User Type (2017-2030)
12.1.4. Market Revenue and Forecast, by Generation Type (2017-2030)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Product (2017-2030)
12.1.5.2. Market Revenue and Forecast, by Application (2017-2030)
12.1.5.3. Market Revenue and Forecast, by End User Type (2017-2030)
12.1.5.4. Market Revenue and Forecast, by Generation Type (2017-2030)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Product (2017-2030)
12.1.6.2. Market Revenue and Forecast, by Application (2017-2030)
12.1.6.3. Market Revenue and Forecast, by End User Type (2017-2030)
12.1.6.4. Market Revenue and Forecast, by Generation Type (2017-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Product (2017-2030)
12.2.2. Market Revenue and Forecast, by Application (2017-2030)
12.2.3. Market Revenue and Forecast, by End User Type (2017-2030)
12.2.4. Market Revenue and Forecast, by Generation Type (2017-2030)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Product (2017-2030)
12.2.5.2. Market Revenue and Forecast, by Application (2017-2030)
12.2.5.3. Market Revenue and Forecast, by End User Type (2017-2030)
12.2.5.4. Market Revenue and Forecast, by Generation Type (2017-2030)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Product (2017-2030)
12.2.6.2. Market Revenue and Forecast, by Application (2017-2030)
12.2.6.3. Market Revenue and Forecast, by End User Type (2017-2030)
12.2.6.4. Market Revenue and Forecast, by Generation Type (2017-2030)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Product (2017-2030)
12.2.7.2. Market Revenue and Forecast, by Application (2017-2030)
12.2.7.3. Market Revenue and Forecast, by End User Type (2017-2030)
12.2.7.4. Market Revenue and Forecast, by Generation Type (2017-2030)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Product (2017-2030)
12.2.8.2. Market Revenue and Forecast, by Application (2017-2030)
12.2.8.3. Market Revenue and Forecast, by End User Type (2017-2030)
12.2.8.4. Market Revenue and Forecast, by Generation Type (2017-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Product (2017-2030)
12.3.2. Market Revenue and Forecast, by Application (2017-2030)
12.3.3. Market Revenue and Forecast, by End User Type (2017-2030)
12.3.4. Market Revenue and Forecast, by Generation Type (2017-2030)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Product (2017-2030)
12.3.5.2. Market Revenue and Forecast, by Application (2017-2030)
12.3.5.3. Market Revenue and Forecast, by End User Type (2017-2030)
12.3.5.4. Market Revenue and Forecast, by Generation Type (2017-2030)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Product (2017-2030)
12.3.6.2. Market Revenue and Forecast, by Application (2017-2030)
12.3.6.3. Market Revenue and Forecast, by End User Type (2017-2030)
12.3.6.4. Market Revenue and Forecast, by Generation Type (2017-2030)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Product (2017-2030)
12.3.7.2. Market Revenue and Forecast, by Application (2017-2030)
12.3.7.3. Market Revenue and Forecast, by End User Type (2017-2030)
12.3.7.4. Market Revenue and Forecast, by Generation Type (2017-2030)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Product (2017-2030)
12.3.8.2. Market Revenue and Forecast, by Application (2017-2030)
12.3.8.3. Market Revenue and Forecast, by End User Type (2017-2030)
12.3.8.4. Market Revenue and Forecast, by Generation Type (2017-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Product (2017-2030)
12.4.2. Market Revenue and Forecast, by Application (2017-2030)
12.4.3. Market Revenue and Forecast, by End User Type (2017-2030)
12.4.4. Market Revenue and Forecast, by Generation Type (2017-2030)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Product (2017-2030)
12.4.5.2. Market Revenue and Forecast, by Application (2017-2030)
12.4.5.3. Market Revenue and Forecast, by End User Type (2017-2030)
12.4.5.4. Market Revenue and Forecast, by Generation Type (2017-2030)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Product (2017-2030)
12.4.6.2. Market Revenue and Forecast, by Application (2017-2030)
12.4.6.3. Market Revenue and Forecast, by End User Type (2017-2030)
12.4.6.4. Market Revenue and Forecast, by Generation Type (2017-2030)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Product (2017-2030)
12.4.7.2. Market Revenue and Forecast, by Application (2017-2030)
12.4.7.3. Market Revenue and Forecast, by End User Type (2017-2030)
12.4.7.4. Market Revenue and Forecast, by Generation Type (2017-2030)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Product (2017-2030)
12.4.8.2. Market Revenue and Forecast, by Application (2017-2030)
12.4.8.3. Market Revenue and Forecast, by End User Type (2017-2030)
12.4.8.4. Market Revenue and Forecast, by Generation Type (2017-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Product (2017-2030)
12.5.2. Market Revenue and Forecast, by Application (2017-2030)
12.5.3. Market Revenue and Forecast, by End User Type (2017-2030)
12.5.4. Market Revenue and Forecast, by Generation Type (2017-2030)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Product (2017-2030)
12.5.5.2. Market Revenue and Forecast, by Application (2017-2030)
12.5.5.3. Market Revenue and Forecast, by End User Type (2017-2030)
12.5.5.4. Market Revenue and Forecast, by Generation Type (2017-2030)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Product (2017-2030)
12.5.6.2. Market Revenue and Forecast, by Application (2017-2030)
12.5.6.3. Market Revenue and Forecast, by End User Type (2017-2030)
12.5.6.4. Market Revenue and Forecast, by Generation Type (2017-2030)
Chapter 13. Company Profiles
13.1. Johnson & Johnson
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Syneron Candela
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Lumenis
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Hologic
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Solta Medical
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Alma Laser
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Galderma
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Dickinson and Company
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Antares Pharma
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Novartis AG
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Buy Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1594
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
0 Comments